Editorial: Combinational immunotherapy of cancer: novel targets, mechanisms, and strategies.
作者信息
Nan Yanyang, Ju Dianwen, Zhang Xuyao
机构信息
Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, China.
出版信息
Front Immunol. 2023 Aug 11;14:1250975. doi: 10.3389/fimmu.2023.1250975. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Combinational immunotherapy of cancer: novel targets, mechanisms, and strategies.社论：癌症的联合免疫疗法：新靶点、机制与策略
Front Immunol. 2023 Aug 11;14:1250975. doi: 10.3389/fimmu.2023.1250975. eCollection 2023.
2
Editorial: Community series in combinational immunotherapy of cancer: novel targets, mechanisms, and strategies, volume II.社论：癌症联合免疫疗法中的社区系列：新靶点、机制与策略，第二卷
Front Immunol. 2023 Aug 11;14:1256691. doi: 10.3389/fimmu.2023.1256691. eCollection 2023.
3
Editorial: Immunotherapy and small molecule inhibitors as combinational cancer therapeutics.社论：免疫疗法与小分子抑制剂作为联合癌症治疗手段
Front Immunol. 2023 Aug 22;14:1270182. doi: 10.3389/fimmu.2023.1270182. eCollection 2023.
4
Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.CD73-腺苷能检查点抑制剂作为常规和先进癌症免疫疗法的有前途的联合治疗药物。
Front Immunol. 2023 Jun 26;14:1212209. doi: 10.3389/fimmu.2023.1212209. eCollection 2023.
5
Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective.联合局部消融与免疫治疗肝细胞癌：原理、疗效与展望。
Front Immunol. 2022 Nov 23;13:1033000. doi: 10.3389/fimmu.2022.1033000. eCollection 2022.
6
Host-Guest Formulation of Carboxylatopillar[6]arene with Ergothioneine as a New Antidote for Combinational Detoxification of Paraquat.柱[6]芳烃与 ergothioneine 的主体-客体包合作用作为百草枯联合解毒的新型解毒剂。
ACS Appl Mater Interfaces. 2023 Jun 7;15(22):26407-26416. doi: 10.1021/acsami.3c03259. Epub 2023 May 23.
7
Toward innovative combinational immunotherapy: A systems biology perspective.走向创新的联合免疫疗法：系统生物学视角。
Cancer Treat Rev. 2018 Jul;68:1-8. doi: 10.1016/j.ctrv.2018.05.003. Epub 2018 May 8.
8
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy.免疫检查点抑制剂与癌症治疗中抗生素相互作用的分析。
Front Med. 2022 Jun;16(3):307-321. doi: 10.1007/s11684-022-0927-0. Epub 2022 Jun 1.
9
Mechanism-directed combinational immunotherapies in liver cancer hold promise.针对肝癌的机制导向性联合免疫疗法前景广阔。
Cell Mol Immunol. 2023 Nov;20(11):1395-1397. doi: 10.1038/s41423-023-01068-z. Epub 2023 Aug 7.
10
Recent Advances of Platinum-Based Anticancer Complexes in Combinational Multimodal Therapy.基于铂的抗癌配合物在联合多模态治疗中的最新进展。
Adv Healthc Mater. 2023 Sep;12(22):e2300253. doi: 10.1002/adhm.202300253. Epub 2023 May 14.
本文引用的文献
1
Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell.重新思考抗原来源：基于全肿瘤细胞/组织裂解物或全肿瘤细胞的癌症疫苗。
Adv Sci (Weinh). 2023 Aug;10(22):e2300121. doi: 10.1002/advs.202300121. Epub 2023 May 31.
2
CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks.基于嵌合抗原受体 T 细胞的免疫疗法和放射疗法：潜力、前景和风险。
Mol Cancer. 2023 May 12;22(1):82. doi: 10.1186/s12943-023-01775-1.
3
Therapy with oncolytic viruses: progress and challenges.溶瘤病毒疗法：进展与挑战。
Nat Rev Clin Oncol. 2023 Mar;20(3):160-177. doi: 10.1038/s41571-022-00719-w. Epub 2023 Jan 11.
4
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.免疫检查点阻断反应、耐药性和毒性的特征。
Cell. 2022 Feb 3;185(3):576. doi: 10.1016/j.cell.2022.01.008.
5
Dendritic cell therapy in cancer treatment; the state-of-the-art.树突状细胞疗法在癌症治疗中的应用：最新进展。
Life Sci. 2020 Aug 1;254:117580. doi: 10.1016/j.lfs.2020.117580. Epub 2020 Mar 20.
6
Top 10 Challenges in Cancer Immunotherapy.癌症免疫疗法的十大挑战。
Immunity. 2020 Jan 14;52(1):17-35. doi: 10.1016/j.immuni.2019.12.011.
Zotero 插件